Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial…

By Dr. Matthew Watson

WARREN, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the first patient has been enrolled in its REBUILD Phase 3 registrational clinical study evaluating INOpulse®, a pulsed inhaled nitric oxide therapy, as a potential treatment for fibrotic interstitial lung disease (fILD).

See the rest here:
Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial...

Related Post


categoriaGlobal News Feed commentoComments Off on Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial… | dataDecember 1st, 2020

About...

This author published 3474 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research